On August 11, WUXI BIO rose 3.08% in regular trading, trading at 47.54 HKD/share, with turnover of 3.79 billion HKD. The gain was driven by clear upward signals across the CXO sector, reinforced by strong peer earnings and the company's recent acquisition activity.

Guojin Securities noted that the CXO industry has completed a full cycle and entered a new recovery phase characterized by synchronized domestic and overseas demand, expansion of novel molecular pipelines, and sequential improvement in orders and earnings. Peer company WuXi AppTec reported H1 revenue of 28.897 billion yuan, up 38.93% YoY, with adjusted net profit surging 89.39% YoY, substantially boosting sector sentiment. WUXI BIO's board is scheduled to review interim results on August 25, with the market holding positive expectations.

Additionally, the company recently announced an agreement to acquire Transcenta's process development and manufacturing facility in Hangzhou to enhance its end-to-end integrated service capabilities and meet rapidly growing client demand, with the transaction expected to close in Q3. The company's MFG8 drug substance facility also recently received FDA Pre-License Inspection approval, marking a key milestone for commercial-scale supply.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)